Infliximab in refractory spondyloarthropathies: a multicentre 38 week open study

[...]the results of this open prospective trial clearly indicate that infliximab is an effective therapeutic option for patients with refractory SpA.

Saved in:
Bibliographic Details
Published in:Annals of the rheumatic diseases 2003-12, Vol.62 (12), p.1239-1240
Main Authors: Collantes-Estévez, E, Muñoz-Villanueva, M C, Cañete-Crespillo, J D, Sanmartí-Sala, R, Gratacós-Masmitjá, J, Zarco-Montejo, P, Torre-Alonso, J C, González-Fernández, C
Format: Article
Language:English
Subjects:
Adult
Antibodies, Monoclonal - therapeutic use
Antirheumatic Agents - therapeutic use
Bowel disease
Confidence intervals
Drug dosages
Drug Resistance
Female
Humans
Inflammation
Infliximab
Letter
Male
Patients
Prospective Studies
Spondylarthropathies - drug therapy
Thoracic Vertebrae
Working groups
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-b569t-e206be0e945f9c3bdd63c91a798c0dd8d457c3c083c72458e51dbc8add8a0c573
cites cdi_FETCH-LOGICAL-b569t-e206be0e945f9c3bdd63c91a798c0dd8d457c3c083c72458e51dbc8add8a0c573
container_end_page 1240
container_issue 12
container_start_page 1239
container_title Annals of the rheumatic diseases
container_volume 62
creator Collantes-Estévez, E
Muñoz-Villanueva, M C
Cañete-Crespillo, J D
Sanmartí-Sala, R
Gratacós-Masmitjá, J
Zarco-Montejo, P
Torre-Alonso, J C
González-Fernández, C
description [...]the results of this open prospective trial clearly indicate that infliximab is an effective therapeutic option for patients with refractory SpA.
doi_str_mv 10.1136/ard.2002.004879
format article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1754394</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A111847766</galeid><sourcerecordid>A111847766</sourcerecordid><originalsourceid>FETCH-LOGICAL-b569t-e206be0e945f9c3bdd63c91a798c0dd8d457c3c083c72458e51dbc8add8a0c573</originalsourceid><addsrcrecordid>eNqFks1v0zAYxi0EYmVw5oYiIXFASmfHTuxwmDQqGBNj7DB2tRz7TesusYOdwPrf49JqAzQJ-WDZ7-_9eOwHoZcEzwmh1ZEKZl5gXMwxZoLXj9CMsErkBa7wYzTDGNOc1RU_QM9iXKcjFkQ8RQcJYonHM3R55trO3tpeNZl1WYA2KD36sMni4J3ZdF6FcRX8oMaVhfguU1k_daPV4MYAGRXZT4CbzA_gsjhOZvMcPWlVF-HFfj9E3z5-uFp8ys-_np4tTs7zpqzqMYc0YgMYala2taaNMRXVNVG8FhobIwwruaYaC6p5wUoBJTGNFiqFFNYlp4foeFd3mJoezO95VCeHkKSEjfTKyr8jzq7k0v-QhJeM1iwVeLMvEPz3CeIoexs1dJ1y4KcoOWEFo2ILvv4HXPspuCQu1eJcsCRoS-U7aqk6kNa1PnXVS3CQmnsHrU3XJ4QQwTivqsTPH-DTMtBb_WDC0S5BBx9j-qg7rQTLrRlkMoPcmkHuzJAyXv35RPf8_vfvZ7ZxhNu7uAo3suKUl_LieiE_X19dXH7h7-Vp4t_u-KZf_7f7L8SjzSw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1777845694</pqid></control><display><type>article</type><title>Infliximab in refractory spondyloarthropathies: a multicentre 38 week open study</title><source>Open Access: PubMed Central</source><creator>Collantes-Estévez, E ; Muñoz-Villanueva, M C ; Cañete-Crespillo, J D ; Sanmartí-Sala, R ; Gratacós-Masmitjá, J ; Zarco-Montejo, P ; Torre-Alonso, J C ; González-Fernández, C</creator><creatorcontrib>Collantes-Estévez, E ; Muñoz-Villanueva, M C ; Cañete-Crespillo, J D ; Sanmartí-Sala, R ; Gratacós-Masmitjá, J ; Zarco-Montejo, P ; Torre-Alonso, J C ; González-Fernández, C</creatorcontrib><description>[...]the results of this open prospective trial clearly indicate that infliximab is an effective therapeutic option for patients with refractory SpA.</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/ard.2002.004879</identifier><identifier>PMID: 14644870</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>England: BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><subject>Adult ; Antibodies, Monoclonal - therapeutic use ; Antirheumatic Agents - therapeutic use ; Bowel disease ; Confidence intervals ; Drug dosages ; Drug Resistance ; Female ; Humans ; Inflammation ; Infliximab ; Letter ; Male ; Patients ; Prospective Studies ; Spondylarthropathies - drug therapy ; Thoracic Vertebrae ; Working groups</subject><ispartof>Annals of the rheumatic diseases, 2003-12, Vol.62 (12), p.1239-1240</ispartof><rights>Copyright 2003 by Annals of the Rheumatic Diseases</rights><rights>COPYRIGHT 2003 BMJ Publishing Group Ltd.</rights><rights>Copyright: 2003 Copyright 2003 by Annals of the Rheumatic Diseases</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b569t-e206be0e945f9c3bdd63c91a798c0dd8d457c3c083c72458e51dbc8add8a0c573</citedby><cites>FETCH-LOGICAL-b569t-e206be0e945f9c3bdd63c91a798c0dd8d457c3c083c72458e51dbc8add8a0c573</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1754394/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1754394/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14644870$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Collantes-Estévez, E</creatorcontrib><creatorcontrib>Muñoz-Villanueva, M C</creatorcontrib><creatorcontrib>Cañete-Crespillo, J D</creatorcontrib><creatorcontrib>Sanmartí-Sala, R</creatorcontrib><creatorcontrib>Gratacós-Masmitjá, J</creatorcontrib><creatorcontrib>Zarco-Montejo, P</creatorcontrib><creatorcontrib>Torre-Alonso, J C</creatorcontrib><creatorcontrib>González-Fernández, C</creatorcontrib><title>Infliximab in refractory spondyloarthropathies: a multicentre 38 week open study</title><title>Annals of the rheumatic diseases</title><addtitle>Ann Rheum Dis</addtitle><description>[...]the results of this open prospective trial clearly indicate that infliximab is an effective therapeutic option for patients with refractory SpA.</description><subject>Adult</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Bowel disease</subject><subject>Confidence intervals</subject><subject>Drug dosages</subject><subject>Drug Resistance</subject><subject>Female</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Infliximab</subject><subject>Letter</subject><subject>Male</subject><subject>Patients</subject><subject>Prospective Studies</subject><subject>Spondylarthropathies - drug therapy</subject><subject>Thoracic Vertebrae</subject><subject>Working groups</subject><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><recordid>eNqFks1v0zAYxi0EYmVw5oYiIXFASmfHTuxwmDQqGBNj7DB2tRz7TesusYOdwPrf49JqAzQJ-WDZ7-_9eOwHoZcEzwmh1ZEKZl5gXMwxZoLXj9CMsErkBa7wYzTDGNOc1RU_QM9iXKcjFkQ8RQcJYonHM3R55trO3tpeNZl1WYA2KD36sMni4J3ZdF6FcRX8oMaVhfguU1k_daPV4MYAGRXZT4CbzA_gsjhOZvMcPWlVF-HFfj9E3z5-uFp8ys-_np4tTs7zpqzqMYc0YgMYala2taaNMRXVNVG8FhobIwwruaYaC6p5wUoBJTGNFiqFFNYlp4foeFd3mJoezO95VCeHkKSEjfTKyr8jzq7k0v-QhJeM1iwVeLMvEPz3CeIoexs1dJ1y4KcoOWEFo2ILvv4HXPspuCQu1eJcsCRoS-U7aqk6kNa1PnXVS3CQmnsHrU3XJ4QQwTivqsTPH-DTMtBb_WDC0S5BBx9j-qg7rQTLrRlkMoPcmkHuzJAyXv35RPf8_vfvZ7ZxhNu7uAo3suKUl_LieiE_X19dXH7h7-Vp4t_u-KZf_7f7L8SjzSw</recordid><startdate>200312</startdate><enddate>200312</enddate><creator>Collantes-Estévez, E</creator><creator>Muñoz-Villanueva, M C</creator><creator>Cañete-Crespillo, J D</creator><creator>Sanmartí-Sala, R</creator><creator>Gratacós-Masmitjá, J</creator><creator>Zarco-Montejo, P</creator><creator>Torre-Alonso, J C</creator><creator>González-Fernández, C</creator><general>BMJ Publishing Group Ltd and European League Against Rheumatism</general><general>BMJ Publishing Group Ltd</general><general>Elsevier Limited</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>200312</creationdate><title>Infliximab in refractory spondyloarthropathies: a multicentre 38 week open study</title><author>Collantes-Estévez, E ; Muñoz-Villanueva, M C ; Cañete-Crespillo, J D ; Sanmartí-Sala, R ; Gratacós-Masmitjá, J ; Zarco-Montejo, P ; Torre-Alonso, J C ; González-Fernández, C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b569t-e206be0e945f9c3bdd63c91a798c0dd8d457c3c083c72458e51dbc8add8a0c573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Bowel disease</topic><topic>Confidence intervals</topic><topic>Drug dosages</topic><topic>Drug Resistance</topic><topic>Female</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Infliximab</topic><topic>Letter</topic><topic>Male</topic><topic>Patients</topic><topic>Prospective Studies</topic><topic>Spondylarthropathies - drug therapy</topic><topic>Thoracic Vertebrae</topic><topic>Working groups</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Collantes-Estévez, E</creatorcontrib><creatorcontrib>Muñoz-Villanueva, M C</creatorcontrib><creatorcontrib>Cañete-Crespillo, J D</creatorcontrib><creatorcontrib>Sanmartí-Sala, R</creatorcontrib><creatorcontrib>Gratacós-Masmitjá, J</creatorcontrib><creatorcontrib>Zarco-Montejo, P</creatorcontrib><creatorcontrib>Torre-Alonso, J C</creatorcontrib><creatorcontrib>González-Fernández, C</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Collantes-Estévez, E</au><au>Muñoz-Villanueva, M C</au><au>Cañete-Crespillo, J D</au><au>Sanmartí-Sala, R</au><au>Gratacós-Masmitjá, J</au><au>Zarco-Montejo, P</au><au>Torre-Alonso, J C</au><au>González-Fernández, C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Infliximab in refractory spondyloarthropathies: a multicentre 38 week open study</atitle><jtitle>Annals of the rheumatic diseases</jtitle><addtitle>Ann Rheum Dis</addtitle><date>2003-12</date><risdate>2003</risdate><volume>62</volume><issue>12</issue><spage>1239</spage><epage>1240</epage><pages>1239-1240</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>[...]the results of this open prospective trial clearly indicate that infliximab is an effective therapeutic option for patients with refractory SpA.</abstract><cop>England</cop><pub>BMJ Publishing Group Ltd and European League Against Rheumatism</pub><pmid>14644870</pmid><doi>10.1136/ard.2002.004879</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0003-4967
ispartof Annals of the rheumatic diseases, 2003-12, Vol.62 (12), p.1239-1240
issn 0003-4967
1468-2060
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1754394
source Open Access: PubMed Central
subjects Adult
Antibodies, Monoclonal - therapeutic use
Antirheumatic Agents - therapeutic use
Bowel disease
Confidence intervals
Drug dosages
Drug Resistance
Female
Humans
Inflammation
Infliximab
Letter
Male
Patients
Prospective Studies
Spondylarthropathies - drug therapy
Thoracic Vertebrae
Working groups
title Infliximab in refractory spondyloarthropathies: a multicentre 38 week open study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T10%3A26%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Infliximab%20in%20refractory%20spondyloarthropathies:%20a%20multicentre%2038%20week%20open%20study&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Collantes-Est%C3%A9vez,%20E&rft.date=2003-12&rft.volume=62&rft.issue=12&rft.spage=1239&rft.epage=1240&rft.pages=1239-1240&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/ard.2002.004879&rft_dat=%3Cgale_pubme%3EA111847766%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b569t-e206be0e945f9c3bdd63c91a798c0dd8d457c3c083c72458e51dbc8add8a0c573%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1777845694&rft_id=info:pmid/14644870&rft_galeid=A111847766&rfr_iscdi=true